Nanobiotix secured a $71 million non‑dilutive loan from HealthCare Royalty to fund operations through early 2028, pledging a portion of future royalties and milestone payments tied to its radiotherapy‑activated nanoparticle NBTXR3 (JNJ‑1900). The facility provides $50 million up front and $21 million contingent; Nanobiotix would repay up to $124 million if sales hit the defined threshold by 2030, or $178 million if later, and HCRx would collect a capped reduced royalty share thereafter. The funding follows prior deal amendments with Johnson & Johnson that shifted development costs and milestone potential; NBTXR3 is designed to amplify local radiation absorption in tumors.